Skip to main content
. 2016 Jul 6;7(31):49722–49732. doi: 10.18632/oncotarget.10437

Figure 4. CK2 inhibitor-TBB suppress the expression of CRLF2 in an IKZF1-dependent manner.

Figure 4

(A–B) Effect of CK2 inhibitor-TBB) which functions as Ikaros activator, on expression of CRLF2 mRNA level (A) and protein level (B) in Nalm6 and CEM cells with TBB treatment for 2 days. (C–D) Effect of CK2 knockdown on the expression of CRLF2 in Nalm6 (C) and CEM (D) cells. (E–F) IKZF1 knockdown rescues the TBB-induced change of CRLF2 in Nalm6 (E) and CEM (F) cells. Cells was treated with 25 μM TBB for 2 days.